CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Abstract excerpt

The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single agent activity in heavily pretreated relapsed and refractory multiple myeloma (MM). However, not all patients respond, and many patients eventually develop progressive disease to daratumumab monotherapy. We therefore examined whether pretreatment expression levels of CD38 and complement-inhibitory proteins (CIPs) are associated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Complement system in diseases
• Share to Multiple Myeloma Research and Treatments
• Share to Peptidase Inhibition and Analysis